Acrivon Therapeutics, Inc. ACRV
1.74 USD +0.07 (+4.19%)
At closeNov 4, 2026, 4:01 PM EST
1.77 +0.03 +1.72%
After hours · Nov 4, 4:01 PM ET
1.66 Day range 1.77
1.27 52-week range 3.56
- YTD
- -27.80%
- 1 year
- -19.07%
Financial health
Altman Z-Score
-2.66 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-3 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 5
Valuation
P/E -1.2×
FY 2020 5y median -2.9× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 0.8×
FY 2020 5y median 0.9× FY 2025
P/FCF -1.4×
FY 2020 5y median -3.4× FY 2025
EV/EBITDA -0.7×
FY 2020 5y median -2.4× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -70.4%
FY 2020 5y median -29.7% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -69.2%
FY 2020 5y median -45.6% FY 2025
ROIC -73.0%
FY 2020 5y median -49.4% FY 2025
ROA -60.1%
FY 2020 5y median -41.0% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income 5.7%
FY 2020 FY 2025
EPS (diluted) 3.8%
FY 2020 FY 2025
Free Cash Flow 4.5%
FY 2020 FY 2025
Financial Health
Current Ratio 7.7×
FY 2020 5y median 10.6× FY 2025
Quick Ratio 7.7×
FY 2020 5y median 10.6× FY 2025
Debt / Equity 0.0×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 0.5×
FY 2020 5y median 0.5× FY 2025
Interest Coverage 0.0×
FY 2020 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31